The Europe Leukemia Therapeutics Market would witness market growth of 5.8% CAGR during the forecast period (2023-2029).
A rise in R&D spending has fueled the market's expansion due to the significant unmet medical demand for leukemia treatments that are more effective. Additionally, as a result of increased technological developments, like the creation of targeted and immunotherapies, there is an increase in demand for leukemia therapeutics that are efficient, which is propelling the market's expansion. Also, rising demand for combination medicines that might offer more thorough treatment modalities.
New combination therapies including chemotherapy and immunotherapy have been developed as a result of this. These factors are helping the market share to increase. Because of the accessibility of better healthcare infrastructure, rising unmet healthcare needs, rising incidences of chronic lymphocytic leukemia, and an upsurge in demand for leukemia therapeutics, the market is anticipated to grow at a rapid rate.
Additionally, the demand for superior health care is growing, the government is making sizable investments to upgrade the healthcare infrastructure, and the medical tourism sector is expanding rapidly in emerging economies. All of these factors are contributing to the rapid growth of the healthcare sector in these economies. The need for leukemia therapeutics is not just present in wealthy nations; it is also present in underdeveloped nations, which stimulates the market's expansion. Targeted therapy usage is increasing, and leukemia early diagnosis and treatment are becoming more well known, which contribute to the market's expansion.
The results of the 2021 Census show that England and Wales' overall population is still becoming older and that a larger proportion of people than ever are in older age groups. 18.6% of the population, or roughly 11 million people, were 65 years of age or older in 2016, an increase from 16.4% in the 2011 census. This includes 527,900 people, or more than 500,000, who were 90 years of age or older. The population's demographics changed between 2011 and 2021, as the median (average) age in England and Wales rose from 39 to 40 years. In Germany, about 25% of the population is over 60 or older, which is expected to climb. As a result, the number of cases of leukemia in the region is anticipated to rise along with the ageing population, which would raise the demand there.
The Germany market dominated the Europe Leukemia Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $775.4 million by 2029. The UK market is anticipated to grow at a CAGR of 4.9% during (2023 - 2029). Additionally, The France market would exhibit a CAGR of 6.6% during (2023 - 2029).
Based on Drug Class, the market is segmented into Targeted Therapy & Immunotherapy and Chemotherapy. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Type, the market is segmented into Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Leukemia Therapeutics Market is Projected to reach USD 11.7 Billion by 2029, at a CAGR of 6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Gilead Sciences, Inc., Bristol Myers Squibb Company, Sanofi S.A., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Lupin Limited, Amgen, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc. and Novartis AG.
By Drug Class
By Distribution Channel
By Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 